166 related articles for article (PubMed ID: 12102740)
1. Defining tumor antigens: mRNA, protein or cytotoxicity?
Lim SH; Periman P; Klug P; Weidanz J; Whitton V; Chiriva-Internati M; Wang Z; Wright S
Trends Immunol; 2002 May; 23(5):236-7; author reply 237-8. PubMed ID: 12102740
[No Abstract] [Full Text] [Related]
2. Oncogene products represent potential targets of tumor vaccines.
Tuttle TM
Cancer Immunol Immunother; 1996 Nov; 43(3):135-41. PubMed ID: 9001566
[No Abstract] [Full Text] [Related]
3. Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?
Shurin MR; Gregory M; Morris JC; Malyguine AM
Expert Opin Biol Ther; 2010 Nov; 10(11):1539-53. PubMed ID: 20955111
[TBL] [Abstract][Full Text] [Related]
4. Protein tumor antigens.
Srivastava PK
Curr Opin Immunol; 1991 Oct; 3(5):654-8. PubMed ID: 1755984
[TBL] [Abstract][Full Text] [Related]
5. [RNA-loaded dendritic cells].
Hinoda Y
Nihon Rinsho; 2005 Apr; 63 Suppl 4():613-8. PubMed ID: 15861719
[No Abstract] [Full Text] [Related]
6. Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.
Krishnadas DK; Wang Y; Sundaram K; Bai F; Lucas KG
Tumour Biol; 2017 Jul; 39(7):1010428317701309. PubMed ID: 28677424
[TBL] [Abstract][Full Text] [Related]
7. Identification of a tumor associated antigen that can induce tumor specific cytotoxicity.
Dunkle A; He YW
Cancer Biol Ther; 2009 May; 8(9):844-5. PubMed ID: 19377280
[No Abstract] [Full Text] [Related]
8. Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy.
Boon T
Int J Cancer; 1993 May; 54(2):177-80. PubMed ID: 8486420
[No Abstract] [Full Text] [Related]
9. Degeneracy instead of specificity: is this a solution to cancer immunotherapy?
Schultze JL
Trends Immunol; 2002 Jul; 23(7):343-4; author reply 344-5. PubMed ID: 12103351
[No Abstract] [Full Text] [Related]
10. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy.
Boon T; Coulie P; Marchand M; Weynants P; Wölfel T; Brichard V
Important Adv Oncol; 1994; ():53-69. PubMed ID: 8206495
[No Abstract] [Full Text] [Related]
11. [Molecular biology of lung cancer series].
Hiret S; Senellart H; Bennouna J
Rev Mal Respir; 2010 Oct; 27(8):954-8. PubMed ID: 20965409
[TBL] [Abstract][Full Text] [Related]
12. MHC-binding peptides as immunotherapeutics for cancer.
Kobayashi H; Kennedy R; Lu J; Davila E; Celis E
Immunol Invest; 2000 May; 29(2):105-10. PubMed ID: 10854176
[No Abstract] [Full Text] [Related]
13. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes for use in cancer immunotherapy.
Ozaki Y; Kontani K; Teramoto K; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Asai T; Ohkubo I
Biochem Biophys Res Commun; 2004 May; 317(4):1089-95. PubMed ID: 15094380
[TBL] [Abstract][Full Text] [Related]
14. [The function of tumor specific antigen (MAGE) in tumor immunotherapy].
Fang JB; Wang L
Sheng Li Ke Xue Jin Zhan; 2005 Jul; 36(3):273-5. PubMed ID: 16270835
[No Abstract] [Full Text] [Related]
15. Pancreatic Cancer Cell Lysis by Cell-Penetrating Peptide-MAGE-A3-Induced Cytotoxic T Lymphocytes.
Batchu RB; Gruzdyn OV; Qazi AM; Mahmud EM; Mostafa G; Weaver DW; Gruber SA
JAMA Surg; 2016 Nov; 151(11):1086-1088. PubMed ID: 27851862
[No Abstract] [Full Text] [Related]
16. T351 protein, a novel tumor associated antigen and potential target for immunotherapy.
Lu J; Kang N; Cui L; Ba D; Cheng S; He W
Cancer Biol Ther; 2009 May; 8(9):835-43. PubMed ID: 19270507
[TBL] [Abstract][Full Text] [Related]
17. Cancer immunotherapy with MAGE antigens.
Coulie PG
Suppl Tumori; 2002; 1(4):S63-5. PubMed ID: 12415826
[No Abstract] [Full Text] [Related]
18. [Rejection antigens of tumors and specific immunotherapy of cancer].
Boon T; Lucas S
Bull Mem Acad R Med Belg; 1996; 151(12):469-79. PubMed ID: 9491625
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic tumor antigens: diagnostic markers and targets for immunotherapy.
Finn OJ
Important Adv Oncol; 1992; ():61-77. PubMed ID: 1374733
[No Abstract] [Full Text] [Related]
20. The potential of melanoma antigen expression in cancer therapy.
Gillespie AM; Coleman RE
Cancer Treat Rev; 1999 Aug; 25(4):219-27. PubMed ID: 10448130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
